Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:BVXV

BiondVax Pharmaceuticals (BVXV) Stock Price, News & Analysis

BiondVax Pharmaceuticals logo

About BiondVax Pharmaceuticals Stock (NASDAQ:BVXV)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$1.26
$1.59
52-Week Range
N/A
Volume
23,000 shs
Average Volume
127,289 shs
Market Capitalization
$2.54 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive BVXV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BiondVax Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

BVXV Stock News Headlines

BiondVax Pharmaceuticals (NASDAQ: BVXV)
SCNI Scinai Immunotherapeutics Ltd.
Did you miss out on Trump’s “birthday gift” to Americans?
While protestors were rallying against “King Trump,” one trader quietly spotted a 15% weekend move tied to his actions. This setup is part of a larger pattern — one that repeats whenever Trump makes waves. Now, veteran trader Larry Benedict is revealing three “Trigger Tickers” that could deliver 2–3X returns… plus a $194 trillion catalyst that could light up the markets.
See More Headlines

BVXV Stock Analysis - Frequently Asked Questions

BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) issued its earnings results on Monday, March, 28th. The company reported ($2.70) earnings per share for the quarter, missing analysts' consensus estimates of ($0.90) by $1.80.

Shares of BiondVax Pharmaceuticals reverse split on the morning of Friday, November 25th 2022.The 1-10 reverse split was announced on Friday, November 25th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Friday, November 25th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

BiondVax Pharmaceuticals (BVXV) raised $10 million in an initial public offering (IPO) on Tuesday, May 12th 2015. The company issued 1,400,000 shares at $7.32 per share. Aegis Capital Corp served as the underwriter for the IPO.

Based on aggregate information from My MarketBeat watchlists, some other companies that BiondVax Pharmaceuticals investors own include Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA), Bristol Myers Squibb (BMY), Gilead Sciences (GILD), Corbus Pharmaceuticals (CRBP) and Pluristem Therapeutics (PSTI).

Company Calendar

Last Earnings
3/28/2022
Today
7/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:BVXV
Employees
33
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$5.80 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
($3.81) per share
Price / Book
N/A

Miscellaneous

Free Float
1,755,000
Market Cap
$2.54 million
Optionable
Not Optionable
Beta
2.37

Social Links

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

This page (NASDAQ:BVXV) was last updated on 7/6/2025 by MarketBeat.com Staff
From Our Partners